Prostate Cancer Localization With a Multiparametric Magnetic Resonance (MR) Approach

Summary

The primary objective of this prospective multi-centre study is to prove the diagnostic accuracy of in vivo 3T multi-modality Magnetic Resonance Imaging (high resolution T2-weighted MRI, DCE-MRI, MRSI and DWI techniques) in distinguishing carcinoma from other prostate tissue. The gold standard for distinguishing the tissue types is the analysis of whole-mount sections of the resected prostate by a genitourinary histopathologist.

Conditions

• Prostate Cancer

Interventions

OTHER

MRI examination

45-minute MRI examination of the prostate and surrounding tissues with T2-weighted MRI, diffusion-weighted MRI, Spectroscopic Imaging and dynamic contrast enhanced imaging

Sponsors & Collaborators

• Siemens AG

  collaborator INDUSTRY

• Mount Vernon Hospital

  collaborator OTHER

• Multi-Imagem and CDPI, Rio de Janeiro, Brasil

  collaborator UNKNOWN

• Norwegian University of Science and Technology

  collaborator OTHER

• University of California, Los Angeles

  collaborator OTHER

• University Hospital, Ghent

  collaborator OTHER

• Johns Hopkins University

  collaborator OTHER

• Medical University of Vienna

  collaborator OTHER

• University Health Network, Toronto

  collaborator OTHER

• Heidelberg University

  collaborator OTHER

• Radboud University Medical Center

  lead OTHER

Principal Investigators

• Tom W Scheenen, PhD · Radiology, Radboud University Nijmegen Medical Centre

• Jurgen J Fütterer, MD PhD · Radiology, Radboud University Nijmegen Medical Centre

Eligibility

Sex

MALE

Healthy Volunteers

No

Timeline & Regulatory

Start

2010-06-30

Primary Completion

2015-08-31

Completion

2019-07-31

Countries

• United States
• Austria
• Belgium
• Canada
• Germany
• Netherlands
• Norway
• United Kingdom

Study Locations